Lymphoma 2021
DOI: 10.36255/exon-publications.lymphoma.2021.radiomics
|View full text |Cite
|
Sign up to set email alerts
|

Radiomics in Malignant Lymphomas

Abstract: Imaging has a pivotal role in the management of lymphoma patients, from the diagnosis to the therapy assessment. Its importance has grown exponentially in the last years thanks to the introduction of 18 F-fluoro-deoxy-glucose positron emission tomography/computed tomography (18FDG-PET/CT) that permitted to design clinical trial in which treatment was adapted on the basis of metabolic response obtained in the early phase of treatment, usually after two cycles of chemotherapy. This approach has been successfully… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 54 publications
(68 reference statements)
0
2
0
Order By: Relevance
“…Radiomics analysis has been emerging as an interesting way to extract information from imaging data, potentially reflecting disease biological features and providing additional promising prognostic biomarkers in several oncological conditions, such as lymphomas 24 . It is possible to get a wide variety of quantitative data in a short amount of time and a non‐invasive way.…”
Section: Discussionmentioning
confidence: 99%
“…Radiomics analysis has been emerging as an interesting way to extract information from imaging data, potentially reflecting disease biological features and providing additional promising prognostic biomarkers in several oncological conditions, such as lymphomas 24 . It is possible to get a wide variety of quantitative data in a short amount of time and a non‐invasive way.…”
Section: Discussionmentioning
confidence: 99%
“…8 More recently the application of the radiomic analysis has increased the number of achievable PET quantitative parameters and consequently the possibility to explore new predictive biomarkers. 9 The metabolic heterogeneity and the maximal distance between the two farthest lesions (D max ) have emerged as new promising predictors of Progression-Free (PFS) and Overall Survival (OS) in patients with lymphomas. 10,11 These two parameters have been proposed substantially as complementary biomarkers to MTV.…”
Section: Funding Informationmentioning
confidence: 99%